Compounds > isoniazid

isoniazid and meropenem

isoniazid has been researched along with meropenem in 16 studies

Research

Studies (16)

TimeframeStudies, this research(%)All Research%
pre-19900 (0.00)18.7374
1990's0 (0.00)18.2507
2000's2 (12.50)29.6817
2010's10 (62.50)24.3611
2020's4 (25.00)2.80

Authors

AuthorsStudies
Benz, RD; Contrera, JF; Kruhlak, NL; Matthews, EJ; Weaver, JL1
Lombardo, F; Obach, RS; Waters, NJ1
Barnes, JC; Bradley, P; Day, NC; Fourches, D; Reed, JZ; Tropsha, A1
Ambroso, JL; Ayrton, AD; Baines, IA; Bloomer, JC; Chen, L; Clarke, SE; Ellens, HM; Harrell, AW; Lovatt, CA; Reese, MJ; Sakatis, MZ; Taylor, MA; Yang, EY1
Afshari, CA; Chen, Y; Dunn, RT; Hamadeh, HK; Kalanzi, J; Kalyanaraman, N; Morgan, RE; van Staden, CJ1
Chen, M; Hu, C; Suzuki, A; Thakkar, S; Tong, W; Yu, K1
Borra, RS; Chopra, S; Das, S; Dasgupta, A; Gatadi, S; Gour, J; Kaul, G; Madhavi, YV; Malasala, S; Nanduri, S; Shukla, M1
Ahmad, MN; Akunuri, R; Chopra, S; Dasgupta, A; Kaul, G; Madhavi, YV; Malasala, S; Nanduri, S; Shukla, M1
Castagnolo, D; Denny, WA; Dos Santos, JL; Fernandes, GFS; Thompson, AM1
Cole, ST; Dhar, N; Ha, YH; Hartkoorn, RC; Sala, C; Schneider, P; Zhang, M1
Aldridge, BB; Ambravaneswaran, V; Fernandez-Suarez, M; Fortune, SM; Heller, D; Irimia, D; Toner, M1
Cole, ST; Hartkoorn, RC; Lechartier, B1
Chuang, YM; Dutta, NK; Hung, CF; Karakousis, PC; Rubin, H; Wu, TC1
DeJesus, MA; Ehrt, S; Engelhart, CA; Healy, C; Ioerger, TR; Lin, K; Park, SW; Rücker, N; Schnappinger, D; Wang, R; Wright, MG; Xu, W1
Kamoshita, F; Karaushi, H; Mitsutake, K; Miyawaki, Y; Seki, M; Watanabe, N1
Alffenaar, JW; Aryal, S; Boorgula, GD; Dheda, K; Gumbo, T; Malinga, L; Raj, P; Shankar, P; Singh, S; Srivastava, S; Thomas, TA1

Reviews

2 review(s) available for isoniazid and meropenem

ArticleYear
DILIrank: the largest reference drug list ranked by the risk for developing drug-induced liver injury in humans.
    Drug discovery today, 2016, Volume: 21, Issue:4

    Topics: Chemical and Drug Induced Liver Injury; Databases, Factual; Drug Labeling; Humans; Pharmaceutical Preparations; Risk

2016
Tuberculosis Drug Discovery: Challenges and New Horizons.
    Journal of medicinal chemistry, 2022, 06-09, Volume: 65, Issue:11

    Topics: Antitubercular Agents; COVID-19 Drug Treatment; Drug Discovery; Humans; Mycobacterium tuberculosis; Tuberculosis

2022

Other Studies

14 other study(ies) available for isoniazid and meropenem

ArticleYear
Assessment of the health effects of chemicals in humans: II. Construction of an adverse effects database for QSAR modeling.
    Current drug discovery technologies, 2004, Volume: 1, Issue:4

    Topics: Adverse Drug Reaction Reporting Systems; Artificial Intelligence; Computers; Databases, Factual; Drug Prescriptions; Drug-Related Side Effects and Adverse Reactions; Endpoint Determination; Models, Molecular; Quantitative Structure-Activity Relationship; Software; United States; United States Food and Drug Administration

2004
Trend analysis of a database of intravenous pharmacokinetic parameters in humans for 670 drug compounds.
    Drug metabolism and disposition: the biological fate of chemicals, 2008, Volume: 36, Issue:7

    Topics: Blood Proteins; Half-Life; Humans; Hydrogen Bonding; Infusions, Intravenous; Pharmacokinetics; Protein Binding

2008
Cheminformatics analysis of assertions mined from literature that describe drug-induced liver injury in different species.
    Chemical research in toxicology, 2010, Volume: 23, Issue:1

    Topics: Animals; Chemical and Drug Induced Liver Injury; Cluster Analysis; Databases, Factual; Humans; MEDLINE; Mice; Models, Chemical; Molecular Conformation; Quantitative Structure-Activity Relationship

2010
Preclinical strategy to reduce clinical hepatotoxicity using in vitro bioactivation data for >200 compounds.
    Chemical research in toxicology, 2012, Oct-15, Volume: 25, Issue:10

    Topics: Chemical and Drug Induced Liver Injury; Cytochrome P-450 Enzyme Inhibitors; Cytochrome P-450 Enzyme System; Decision Trees; Drug Evaluation, Preclinical; Drug-Related Side Effects and Adverse Reactions; Glutathione; Humans; Liver; Pharmaceutical Preparations; Protein Binding

2012
A multifactorial approach to hepatobiliary transporter assessment enables improved therapeutic compound development.
    Toxicological sciences : an official journal of the Society of Toxicology, 2013, Volume: 136, Issue:1

    Topics: Animals; ATP Binding Cassette Transporter, Subfamily B; ATP Binding Cassette Transporter, Subfamily B, Member 11; ATP-Binding Cassette Transporters; Biological Transport; Chemical and Drug Induced Liver Injury; Cluster Analysis; Drug-Related Side Effects and Adverse Reactions; Humans; Liver; Male; Multidrug Resistance-Associated Proteins; Pharmacokinetics; Rats; Rats, Sprague-Dawley; Recombinant Proteins; Risk Assessment; Risk Factors; Toxicity Tests

2013
Synthesis of 1,2,3-triazole linked 4(3H)-Quinazolinones as potent antibacterial agents against multidrug-resistant Staphylococcus aureus.
    European journal of medicinal chemistry, 2018, Sep-05, Volume: 157

    Topics: Anti-Bacterial Agents; Dose-Response Relationship, Drug; Methicillin-Resistant Staphylococcus aureus; Microbial Sensitivity Tests; Molecular Structure; Quinazolinones; Staphylococcal Infections; Structure-Activity Relationship; Triazoles

2018
Synthesis and evaluation of new quinazoline-benzimidazole hybrids as potent anti-microbial agents against multidrug resistant Staphylococcus aureus and Mycobacterium tuberculosis.
    European journal of medicinal chemistry, 2021, Feb-15, Volume: 212

    Topics: Anti-Bacterial Agents; Benzimidazoles; Dose-Response Relationship, Drug; Microbial Sensitivity Tests; Molecular Structure; Mycobacterium tuberculosis; Quinazolines; Staphylococcus aureus; Structure-Activity Relationship

2021
Simple model for testing drugs against nonreplicating Mycobacterium tuberculosis.
    Antimicrobial agents and chemotherapy, 2010, Volume: 54, Issue:10

    Topics: Antitubercular Agents; Aza Compounds; Fluoroquinolones; Isoniazid; Meropenem; Moxifloxacin; Mycobacterium tuberculosis; Nitroimidazoles; Quinolines; Rifampin; Streptomycin; Thienamycins

2010
Asymmetry and aging of mycobacterial cells lead to variable growth and antibiotic susceptibility.
    Science (New York, N.Y.), 2012, Jan-06, Volume: 335, Issue:6064

    Topics: Anti-Bacterial Agents; Cell Cycle; Cell Division; Cell Wall; Cycloserine; Escherichia coli; Isoniazid; Meropenem; Microbial Sensitivity Tests; Microfluidic Analytical Techniques; Mycobacterium smegmatis; Mycobacterium tuberculosis; Rifampin; Thienamycins; Time Factors

2012
In vitro combination studies of benzothiazinone lead compound BTZ043 against Mycobacterium tuberculosis.
    Antimicrobial agents and chemotherapy, 2012, Volume: 56, Issue:11

    Topics: Adamantane; Antitubercular Agents; Aza Compounds; Diarylquinolines; Drug Combinations; Drug Synergism; Ethambutol; Ethylenediamines; Fluoroquinolones; Isoniazid; Meropenem; Microbial Sensitivity Tests; Microbial Viability; Moxifloxacin; Mycobacterium tuberculosis; Nitroimidazoles; Quinolines; Rifampin; Spiro Compounds; Thiazines; Thienamycins

2012
Stringent Response Factors PPX1 and PPK2 Play an Important Role in Mycobacterium tuberculosis Metabolism, Biofilm Formation, and Sensitivity to Isoniazid In Vivo.
    Antimicrobial agents and chemotherapy, 2016, Volume: 60, Issue:11

    Topics: Acid Anhydride Hydrolases; Animals; Antitubercular Agents; Biofilms; Citric Acid Cycle; Clofazimine; Disease Models, Animal; Drug Resistance, Bacterial; Gene Expression; Glycerophosphates; Isoenzymes; Isoniazid; Meropenem; Mice; Mycobacterium tuberculosis; Naphthoquinones; Phosphotransferases (Phosphate Group Acceptor); Polyphosphates; Thienamycins; Tuberculosis Vaccines; Tuberculosis, Multidrug-Resistant; Vaccines, DNA; Xylose

2016
Chemical Genetic Interaction Profiling Reveals Determinants of Intrinsic Antibiotic Resistance in Mycobacterium tuberculosis.
    Antimicrobial agents and chemotherapy, 2017, Volume: 61, Issue:12

    Topics: Adenosine Triphosphatases; Antitubercular Agents; Bacterial Proteins; Cell Wall; Drug Resistance, Multiple, Bacterial; Ethambutol; Galactans; Gene Expression Profiling; Gene Expression Regulation, Bacterial; Humans; Ion Pumps; Isoniazid; Ligases; Mannosyltransferases; Membrane Transport Proteins; Meropenem; Microbial Sensitivity Tests; Mycobacterium tuberculosis; Mycolic Acids; Peptidoglycan; Rifampin; Serine Proteases; Thienamycins; Vancomycin

2017
A Mycobacterium tuberculosis-Infected Patient Who Could Not Tolerate Oral Intake Successfully Treated Using an Intravenous Tedizolid-Containing Regimen.
    The American journal of case reports, 2022, Oct-10, Volume: 23

    Topics: Aged; Anti-Bacterial Agents; Antitubercular Agents; Cutaneous Fistula; Ethambutol; Humans; Isoniazid; Levofloxacin; Linezolid; Male; Meropenem; Micafungin; Mycobacterium tuberculosis; Oxazolidinones; Pyrazinamide; Rifampin; Streptomycin; Teicoplanin; Tetrazoles; Tuberculosis

2022
Meropenem-vaborbactam restoration of first-line drug efficacy and comparison of meropenem-vaborbactam-moxifloxacin versus BPaL MDR-TB regimen.
    International journal of antimicrobial agents, 2023, Volume: 62, Issue:6

    Topics: Antitubercular Agents; beta-Lactamase Inhibitors; Humans; Isoniazid; Linezolid; Meropenem; Moxifloxacin; Mycobacterium tuberculosis; Rifampin; Tuberculosis, Multidrug-Resistant

2023